Please assess the completion status of the following clinical trial:

Trial Title: Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients that are willing and able to provide written informed consent~* age ≥ 18 years~* HCV RNA ≥ 103 IU/mL~* HCV genotype 1 or 4~* screening ultrasound excluding hepatocellular carcinoma (HCC)~* acceptable laboratory values (hemoglobin ≥8.0 g/dL, platelet count ≥40,000/mm3; AST, ALT, and alkaline phosphatase ≤10 × ULN; creatinine clearance ≥30 mL/min)~* general good health~* ability to comply with study procedures~* HIV-infected patients must have completed at least 6 months of any approved HIV antiretroviral therapy (ART) per Rwanda National Guidelines 2013, have been taking for at least 2 weeks prior to screening ART compatible with SOF/LDV (efavirenz, rilpivirine, raltegravir, dolutegravir, emtricitabine, lamivudine, zidovudine, tenofovir), have screening HIV RNA \< 200 copies/mL, and have screening CD4 T-cell count of ≥100 cells/µL~Exclusion Criteria:~* current or history of clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage)~* active tuberculosis~* other clinically-significant illness (except HCV and/or HIV) or any other major medical disorder~* active Hepatitis B infection~* difficulty with blood collection and/or poor venous access for the purposes of phlebotomy~* any IFN-containing regimen within 8 weeks prior to screening or any prior exposure to HCV-specific direct-acting antiviral agent (other than a NS3/4A protease inhibitor and SOF), current pregnancy or breastfeeding, and active drug or alcohol use or dependence

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Harvoni (Type: OTHER): sofosbuvir/ledipasvir once daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).